Filtered By:
Condition: Heart Failure
Countries: Norway Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation
ConclusionsThe uptake of DOACs was rapid and spurred an increase in new users of oral anticoagulants for atrial fibrillation from 2010 to 2015 in Norway. The mean CHA2DS2-VASc score did not change substantially during this period. Vascular disease, heart failure, and diabetes were associated with initiation of warfarin, and previous stroke, age 65 –74 and female sex with initiation of DOACs.
Source: European Journal of Clinical Pharmacology - August 16, 2018 Category: Drugs & Pharmacology Source Type: research

Effects of introducing a fee for “bed blockers” on adverse events among patients hospitalized for chronic obstructive pulmonary disease, heart failure, hip fracture and stroke
Conclusion: Overall, there is no strong evidence to suggest that the Norwegian healthcare Coordination Reform is functioning in a manner that exacerbates risk for readmissions or death among the patients considered in this study. Even so, patients with heart failure appear somewhat vulnerable.   Published on 2018-10-23 00:00:00
Source: International Journal of Integrated Care - October 22, 2018 Category: Nursing Source Type: research

High ward occupancy, bedspacing, and 60  day mortality for patients with myocardial infarction, stroke, and heart failure
ConclusionsPatients with heart failure had higher risk of admission to alternate wards when home ward occupancy was high. These patients may be negatively affected by full wards.
Source: ESC Heart Failure - March 29, 2022 Category: Cardiology Authors: Andreas Asheim, Sara Marie Nilsen, Stina Aam, Kjartan Sarheim Anthun, Fredrik Carlsen, Imre Janszky, Lars Johan Vatten, Johan H åkon Bjørngaard Tags: Original Article Source Type: research

Admission Serum Calcium Level and Short-Term Mortality After Acute Ischemic Stroke: A Secondary Analysis Based on a Norwegian Retrospective Cohort
ConclusionACSC is positively associated with 30-day mortality in IS patients, and the relationship between them is linear.
Source: Frontiers in Neurology - June 15, 2022 Category: Neurology Source Type: research

The Outcome of Status Epilepticus and Long-Term Follow-Up
Conclusion: This study highlights the importance of regular care and patient follow-up. Introduction Status epilepticus (SE) is a condition and most extreme form of epilepsy (1), which leads to abnormal and prolonged seizure (at least 5 min). In case SE persists over 30 min, it may have severe long-term consequences (2). Referring to the new classification scheme of SE, there are two operational dimensions of the definition: time point 1 (T1) is associated with abnormally prolonged seizure, when therapy should be initiated, while time point 2 (T2) is related to the time of on-going seizure activity involving a risk...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

Effects of introducing a fee for “inpatient overstays” on the rate of death and readmissions across municipalities in Norway
This study examines the effects of the reform on the rate of death and readmissions occurring within 60 days of hospitalization. We use aggregated municipal data for years 2009, 2010, 2012–2014 (N = 1646) for Norwegian patients (age 18+) hospitalized in the same years for COPD/asthma, heart failure, hip fracture, and stroke. We stratify our analyses of the municipal data by these patient groups. Our linear regression models test for moderated (interaction) effects whereby associations between the reform and the rate of death and readmissions vary by whether or not patients were classified as ready for discharge and in ...
Source: Social Science and Medicine - April 11, 2019 Category: Psychiatry & Psychology Source Type: research

Effects of introducing a fee for inpatient overstays on the rate of death and readmissions across municipalities in Norway
This study examines the effects of the reform on the rate of death and readmissions occurring within 60 days of hospitalization. We use aggregated municipal data for years 2009, 2010, 2012–2014 (N = 1646) for Norwegian patients (age 18+) hospitalized in the same years for COPD/asthma, heart failure, hip fracture, and stroke. We stratify our analyses of the municipal data by these patient groups. Our linear regression models test for moderated (interaction) effects whereby associations between the reform and the rate of death and readmissions vary by whether or not patients were classified as ready for discharge and in ...
Source: Social Science and Medicine - April 24, 2019 Category: Psychiatry & Psychology Source Type: research

Dapagliflozin Compared to DPP ‐4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All‐cause Mortality in Type 2 Diabetes Patients (CVD‐REAL Nordic): a multinational observational study
ConclusionsDapagliflozin was associated with lower risks of cardiovascular events and all‐cause mortality compared to DPP‐4i in a in a real‐world clinical setting and broad T2D population.
Source: Diabetes, Obesity and Metabolism - August 1, 2017 Category: Endocrinology Authors: F Persson, T Nystr öm, M E Jørgensen, B Carstensen, H L Gulseth, M Thuresson, P Fenici, D Nathanson, J W Eriksson, A Norhammar, J Bodegard, K I Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Dapagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
ConclusionsDapagliflozin was associated with lower risks of CV events and all‐cause mortality compared with DPP‐4 inhibitors in a real‐world clinical setting and a broad T2D population.
Source: Diabetes, Obesity and Metabolism - September 8, 2017 Category: Endocrinology Authors: Frederik Persson, Thomas Nystr öm, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegard, Kåre I. Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Does a history of cardiovascular disease or cancer affect mortality after SARS-CoV-2 infection?
Abstract BACKGROUND: Cardiovascular disease and cancer have been described as possible risk factors for COVID-19 mortality. The purpose of this study was to investigate whether a history of cardiovascular disease or cancer affects the risk of dying after a COVID-19 diagnosis in Norway. MATERIAL AND METHOD: Data were compiled from the Norwegian Surveillance System for Communicable Diseases, the Norwegian Cardiovascular Disease Registry and the Cancer Registry of Norway. Univariable and multivariable regression models were used to calculate both relative and absolute risk. RESULTS: In the first half of 20...
Source: Tidsskrift for den Norske Laegeforening - February 2, 2021 Category: General Medicine Authors: Kvåle R, Bønaa KH, Forster R, Gravningen K, Júlíusson PB, Myklebust TÅ Tags: Tidsskr Nor Laegeforen Source Type: research

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research